ArticleJNMA; journal of the Nepal Medical Association2023
Dyslipidemia among Patients with Type 2 Diabetes Mellitus Visiting a Tertiary Care Centre.
Article in JNMA; journal of the Nepal Medical Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.
- Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis StudiesEndocrine, metabolic & immune disorders drug targets · 2026Pooled it
- Clinical Significance of Lipoprotein and Ceruloplasmin Variations in Type 2 Diabetes Mellitus: A Cross-Sectional Study in Owo, Nigeria.Rwanda journal of medicine and health sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A triad of lipid and lipoprotein metabolism is known as dyslipidemia. Dyslipidemia is one of the major risk factors for cardiovascular diseases in diabetes mellitus which is a leading cause of morbidity and mortality worldwide. The aim of the study was to find out the prevalence of dyslipidemia among patients with type 2 diabetes mellitus visiting a tertiary care centre. Methods: A descriptive cross-sectional study was conducted in a tertiary care centre among patients with type 2 diabetes mellitus from 18 February 2020 to 18 August 2020 after obtaining ethical clearance from the Institutional Review Committee. Demographic and blood samples were analysed and recorded using validated and calibrated tools. A convenience sampling technique was used. The point estimate was calculated at a 95% Confidence Interval. Results: Out of 390 patients with type 2 diabetes mellitus, 343 (87.95%) (84.72-91.18, 95% Confidence Interval) had dyslipidemia. The most prevalent dyslipidemia was high low-density lipoprotein cholesterol at 85 (24.78%) followed by mixed dyslipidemia at 305 (88.92%). Conclusions: The prevalence of dyslipidemia among patients with type 2 diabetes mellitus was found to be higher than studies conducted in similar settings. We recommend regular testing of blood glucose and blood lipid levels for early detection of dyslipidemia and putting them under medical supervision to reduce the unwanted complications of cardiovascular diseases. Keywords: cardiovascular disease; dyslipidemia; prevalence; type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.